pain parameters that were greater than those reported by outpatients with cancer. A better understanding of these differences is pertinent to improving pain outcomes. Ó 2017 by the American Society for Pain Management Nursing
Outpatients with sickle cell disease (SCD) (Wilkie et al., 2010b) obtained McGill Pain Questionnaire scores greater than literature-based normative scores for patients with cancer (Wilkie, Savedra, Holzemer, Tesler, & Paul, 1990) , but statistical comparison of pain scores of adult outpatients with SCD and those with cancer was not possible because standard deviations were unavailable for the normative scores. Normative scores, one of the psychometric properties of an instrument, are the typical (usual) values obtained when the instrument is used in a specific population at a defined period that can be used as a reference for comparison with other populations or time points. Two decades ago, experts suggested that SCD pain treatment protocols should be modeled after protocols developed for cancer pain treatment (Ballas, Rubin, & Gabuzda, 1992; Brookoff & Polomano, 1992; Portenoy, 1992; Smith, 1992) . Subsequent debate occurred among sickle cell investigators about how to quantify and treat SCD pain (Ballas et al., 1992; Brookoff & Polomano, 1992; Portenoy, 1992; Smith, 1992) . However, studies in which investigators compared pain in patients with cancer and those with SCD have not been reported. The purpose of this study was to compare multidimensional pain outcomes reported by adult outpatients living with cancer or SCD. This information will be helpful for planning future research of appropriate pain treatment protocols for different pain populations.
Sickle cell disease is an inherited blood disorder affecting about 100,000 Americans, mostly of African descent (National Institutes of Health, National Heart, Lung and Blood Institute, 2009). Pain, the hallmark symptom of SCD, is intractable and disabling, adversely affecting patients' and their families' productivity and quality of life. Pain is also the key reason for the approximately 197,333 annual emergency department (ED) visits by patients with SCD between 1999 and 2007, with 11% encounters attributed to chest pain and 67% of the visits credited to other or unspecified pain (Yusuf, Atrash, Grosse, Parker, & Grant, 2010) . Sickle cell pain is inadequately managed and associated with lack of provider knowledge (Whiteman et al., 2015) , negative attitude of providers toward patients with SCD (Labbe, Herbert, & Haynes, 2005) , discrimination (Haywood et al., 2014) , stigma (Bediako et al., 2014) , and health care injustice that patients with SCD report encountering in their pursuit for adequate pain control (Ezenwa, Molokie, Suarez, Yao, & Wilkie, 2015; Ezenwa et al., 2017; Zempsky, 2009) , lack of objective clinical findings of pain (Ballas, 2005) , and concerns about addiction and ''pseudo-addiction'' (Wright & Adeosum, 2009 ). Consequently, providers often misinterpret patients' needs for opioids as an aberrant drug-seeking behavior (Martin & Moore, 1997) .
Others suggest that sickle cell pain is poorly controlled because the usual pain treatment protocol used in this population is inconsistent with the frequent, severe, complex, and lifelong nature of sickle cell pain (Brookoff & Polomano, 1992) . To improve pain control in patients with SCD, a group of researchers suggested that SCD should be treated with pain treatment protocols similar to those used in the cancer population (Brookoff & Polomano, 1992) . For example, Brookoff and Polomano (1992) , in a longitudinal study of 50 SCD patients prone to use of the ED and inpatient care for pain control, examined the effects of implementing a cancer pain treatment model in patients with SCD. This model included intravenous and oral controlled-release morphine as opposed to intramuscular meperidine and short-acting oral opioid analgesics. The authors observed a significant reduction in ED visits (67%), number of admissions (44%), total inpatient days (57%), and length of hospital stay (23%) after implementation of the morphine protocol (Brookoff & Polomano, 1992) . Lower acute health care utilization in these patients remained at lower levels 1 year after the study (Brookoff & Polomano, 1992) . Despite these positive findings, SCD experts contended that SCD pain is different from cancer pain, requiring SCD pain protocols rather than cancer pain protocols (Ballas et al., 1992; Brookoff & Polomano, 1992; Portenoy, 1992; Smith, 1992) . However, studies have not been conducted to compare the characteristics of cancer pain and SCD pain. Observational studies focused on comparison of the sensory nature of sickle cell pain and cancer pain would add additional evidence to inform the design of trials for SCD pain treatment protocols based on cancer pain management concepts and provide a relative frame of reference for SCD so that providers may better understand and thereby improve management of SCD pain.
There is a variety of disparities in pain management in the United States (Bernabei et al., 1998; Green, Baker, Smith, & Sato, 2003; Meghani, Byun, & Gallagher, 2012; Vallerand, Hasenau, Templin, & Collins-Bohler, 2005) . For the purposes of this article, we focus on disparities in pain management caused by race and disease. A series of three studies conducted by Todd et al. (1993 Todd et al. ( , 1994 Todd et al. ( , 2000 in emergency departments revealed the suboptimal pain treatment that racial minority patients with isolated long bone fractures received compared with their Caucasian counterparts (Todd, Samaroo, & Hoffman, 1993; Todd, Lee, & Hoffman, 1994; Todd, Deaton, D'Adamo, & Goe, 2000) . The pervasiveness of racial disparities in pain management in the United States was brought to fore in a comprehensive literature review (Ezenwa, Ameringer, Ward, & Serlin, 2006) and a systematic review (Cintron & Morrison, 2006) . Based on analysis of the studies reviewed, Ezenwa et al. (2006) reported that although the magnitude of the reported racial and ethnic disparities was overall small, minority patients continued to suffer with pain when there are available pain treatment modalities to alleviate their pain (Ezenwa et al., 2006) . Findings from Cintron and Morrison, 2006 systematic review indicated that health care providers underestimated the pain severity of minorities, were less likely to record pain scores reported by minorities, and were less likely to give opioid analgesics to minority patients than to non-minority patients (Cintron & Morrison, 2006) . The reason for the racial disparities in pain management was a gap that Ezenwa and Fleming (2012) addressed and found that perceived discrimination was one of the explanatory factors; another group of researchers found that perception of control over pain could explain the disparities they found in patients with cancer (Vallerand et al., 2005) .
Although pain management researchers have made strides in understanding racial disparities in pain management, completely absent from the pain management literature is research evidence regarding disparities in pain management with a focus on contrasting disease conditions such as SCD, cancer, and other pain patient populations in a single study. The source or trajectory of pain may differ by disease condition. Understanding any disparities in pain management between disease groups could provide insights into strategies that are advantageous for optimal pain management.
The aim of this study was to determine whether outpatients with SCD report: (1) more severe sensory pain (location, intensity, quality, and pattern); (2) worse pain relative to their expectation; and (3) greater dissatisfaction with their pain level than outpatients with cancer. A sample of outpatients with SCD, which is predominantly African American, will serve as our referent group. Access to a predominately Caucasian (race-discordant) cancer outpatient sample, a predominately African American (race-concordant) cancer outpatient sample, and a SCD outpatient sample, along with observations from one prior study, prompted our comparisons of race-discordant and race-concordant cancer groups with a SCD group. Because African Americans are a known pain disparity group (Bernabei et al., 1998; Green et al., 2003; Meghani et al., 2012; Vallerand et al., 2005) , we expected that the cancer race-discordant group would have less pain than the cancer race-concordant group and the SCD group and that the cancer raceconcordant and SCD groups would have similar pain.
METHODS Design
This study was a comparative secondary analysis study. The institutional review boards of the participating institutions approved this study.
Settings
The primary research studies were conducted in two university-affiliated outpatient oncology clinics in the Northwest and Midwest and one university-affiliated outpatient sickle cell clinic in the Midwest. The Midwest clinics were part of a large minority-serving institution.
Participants
Subject eligibility and exclusion criteria are summarized in Table 1 . Included in this study were 415 outpatients from three studies: (1) 106 patients with SCD, 93% African American (referent group), mean age 34.2 AE 11.2 years; (2) 140 patients with cancer, 90% Caucasian (race discordant), mean age 50.7 AE 12.7 years; and (3) 169 patients with cancer, 20% Caucasian, 65% African American (race concordant), mean age 54.1 AE 13.1 years. The samples differed by age (p < .001), with the SCD sample being 20 years younger than either of the cancer samples. Subjects' sociodemographic information is summarized in Table 2 .
Procedures
Patients were recruited during an outpatient clinic visit. The registered nurses or physicians referred the patients to the study and introduced the patients to the trained researcher. The researcher screened patients for eligibility, explained the study to them, and obtained informed consent. After giving informed consent, patients completed the study questionnaires using a Pentablet computer. a. Marked their pain sites on anterior and posterior views of a body outline drawing b. Reported their current, least, and worst pain intensity during the last 24 hours on a scale of 0 to 10, where 0 is ''no pain'' and 10 is ''pain as bad as it could be'' c. Selected from a 78-word list ranked by severity in 20 groups to report their usual pain quality: for example, shooting, burning, cramping, and so forth. Each of the 78 words is scored as selected or not selected. Calculated from the 20 groups of verbal descriptors, the pain rating index total (PRI-T) ranges from 0 to 78. Normative scores for the PRI-T have been reported (Wilkie et al., 1990) 
The total pattern score ranges from 0 to 6, with higher scores representing more complex pain patterns. Construct validity of the pain pattern score is supported by significant differences in pain location, intensity, and quality scores by pain pattern (Ngamkham, Holden, & Wilkie, 2011) . 2. Pain expectation was measured by PAINReportIt with a single item that asks patients to report their current pain level relative to their expectation. The response options were worse than expected, same as expected, and not as bad as expected. The validity of this measure has been reported in both patients with SCD and those with cancer (Jha et al., 2010) . 3. Satisfaction with pain level was measured with PAINReportIt. One single-item question asks the patients their satisfaction with their pain level. This question has no qualifiers, such as now, usual, or within 24 hours, but it follows the items on pain now and least and worst pain in the past 24 hours. A three-choice response allows the patient to indicate yes, no, or not sure. This item has been found to be valid in both SCD and cancer samples (Ezenwa et al., 2016a; Golas, Park, & Wilkie, 2016; Jha et al., 2010) . 4. Questions regarding demographic characteristics also are included in PAINReportIt. Patients reported their age, gender, ethnicity, marital status, level of education, annual family income, prior use of computers, and current access to computers. We collected these data for the purpose of describing sample characteristics.
Statistical Analysis
We analyzed data using R, a free software environment used for statistical analyses and creating graphics (R Core Team, 2014 Selected all patients with pain of $3/10 to make the pain eligibility for this sample comparable to that of the other two samples (race concordant and SCD).
computed for demographic variables and the pain outcome measures. The c 2 test, Fisher's test, and analysis of variance (ANOVA) were used to compare groups on demographic variables. To compare the three groups on continuous pain measures, we used ANOVA. For group comparison of ordinal pain variables (i.e., pain expectation and satisfaction with pain level), we performed, for each outcome measure, likelihood ratio tests of two nested ordinal regression models, one without the group predictor versus one with it. Tukey's post hoc test was used for multiple pairwise comparisons if the omnibus tests revealed significant difference between study settings.
RESULTS

General Description of Study Variables
The descriptive statistics for the study's demographic variables are reported in Table 2. Table 3 presents descriptive statistics for the pain variables.
Number of Pain Sites
The number of pain sites by study sample is outlined in Table 3 and illustrated in Figure 1 . The two cancer samples did not differ significantly (p ¼ .12), with a mean (SD) of 2.3 (2.0) sites for the race-discordant group and 1.9 (1.4) sites for the race-concordant. The SCD sample reported 3.5 (2.1) sites on average, which was significantly higher than the value for either of the two cancer samples (p < .001 for both).
Worst Pain Intensity
Mean scores for the worst pain intensity in the past 24 hours by study sample are outlined in Table 3 and illustrated in Figure 2 . There was a statistically significant difference between the three samples. The raceconcordant cancer sample reported a mean worst pain intensity of 6.6 (2.7), significantly higher than that of either the race-discordant cancer sample (mean ¼ 5.5, SD ¼ 2.0, p ¼ .002) or the SCD sample (mean ¼ 5.0, SD ¼ 3.3, p < .001). The difference between the race-discordant cancer sample and the SCD sample was not statistically significant.
Pain Quality
Mean pain rating index scores (PRI-T) by study sample are summarized in Table 3 and illustrated in Figure 3 . The race-concordant cancer sample reported PRI-T scores similar to those of the race-discordant cancer sample (p ¼ .92), with means (SD) of 25.6 (15.5) and 26.2 (12.5), respectively. The average PRI-T score of the SCD sample was 34.5 (17.0), significantly higher than that of either cancer sample (p < .001 for both).
Pain Pattern
Mean scores for the pain pattern by study sample are summarized in Table 3 and illustrated in Figure 4 . The two cancer samples reported similar mean (SD) pain pattern scores, 2.5 (1.6) for race discordant and 2.7 (1.9) for race concordant, with p ¼ .52. The SCD sample reported significantly higher pain pattern scores, 3.8 (1.7) with p < .001, compared with that of either cancer sample.
Expectation About Pain
The distributions of responses to the expectations about pain item by study sample are outlined in Table 3 and illustrated in Figure 5 . Comparison of the three samples revealed that the differences among the groups on expectation about pain were marginally significant (p ¼ .048). Post hoc comparison revealed that the race-discordant group reported a significantly worse outcome compared with the SCD sample (p ¼ .038). The differences between the raceconcordant cancer group and the other two groups were not statistically significant.
Satisfaction with Pain Level
The distributions of responses to the satisfaction with pain level item by study sample are outlined in Table 3 and illustrated in Figure 6 . Comparison of the three samples revealed statistically significant differences among the samples, p ¼ .008. The pairwise comparison revealed the race-concordant cancer group to be more dissatisfied than the SCD group (p ¼ .006), but nonsignificant difference between the race-discordant and SCD (p ¼ .13) and between the race-discordant and race-concordant cancer groups (p ¼ .44).
DISCUSSION
The results of the first statistical comparison between outpatients with cancer and those with SCD on sensory pain, pain expectation, and satisfaction with pain level indicate that compared with the two samples of outpatients with cancer, outpatients with SCD at a regularly scheduled clinic visit reported a significantly greater number of pain location sites, higher pain quality, and higher pattern scores. However, the outpatients with cancer who are predominantly African Americans reported greater worst pain intensity in the previous 24 hours than the outpatients with cancer who are predominantly Caucasians or outpatients with SCD. Regarding expectation about pain, the SCD sample reported a better outcome than the race discordant sample (p ¼ .038). Outpatients with SCD reported greater satisfaction with their pain level than the outpatients with cancer who are predominantly African Americans, but did not differ from the outpatients with cancer who are predominantly Caucasians on satisfaction with pain level.
Findings from this analysis suggest that race was a potential factor for worst pain in the cancer samples as the race-concordant group reported significantly higher pain than the race-discordant group. These findings are consistent with the findings within the disparity literature that African Americans with cancer are more likely to report greater pain intensity than Caucasians with cancer (Green et al., 2003; Stephenson, Dalton, Carlson, Youngblood, & Bailey, 2009; Vallerand et al., 2005) . Inconsistent with the pain literature is the fact that patients with SCD reported pain intensity lower than that reported by the race-concordant cancer sample. Given that both groups comprised a majority of African Americans, one would expect that both groups would report greater worst pain intensity than the race-discordant cancer group composed of predominantly Caucasian patients. Other factors such as the stage of disease or the fact that patients with cancer could have preexisting chronic pain may explain this finding.
Findings also suggest that disease was a potential factor for pain location sites, pain quality, pain pattern, expectation, and satisfaction with pain level, as there were significant differences between the SCD group and one or both of the cancer samples but not between the two cancer groups. These findings underscore the disparities between SCD and cancer as disease types. Traditionally, patients with cancer pain have garnered sympathy for their pain not only from their health care providers but also from the public. Much of the public support is related to the media campaign mounted by cancer organizations, foundations, and friends and families of cancer survivors on the monstrous nature of cancer pain. As a result, colossal funds have flooded toward the treatment of cancer and pain associated with it. In comparison, patients with SCD have not received such support from their health care providers, the public, or the media. The SCD community has not been as effective as the cancer community in mounting media campaigns and successfully recruiting celebrities who can champion their cause about the destructive nature of sickle cell pain. The lack of research funding for SCD pain has slowed the progress related to pain care for these patients. For example, SCD was discovered more than 100 years ago, but pain researchers are still unraveling the nuances of sickle cell pain, including its neuropathic component, which was discovered using both sickle cell knockout mice (He et al., 2016) and, in humans, quantitative sensory testing (Campbell et al., 2016; Ezenwa et al., 2016b) . These emerging findings may require a paradigm shift in pain management of sickle cell pain as was possible in cancer pain management, but they need to be confirmed as more research findings become available. Although the SCD group reported larger number of pain sites, pain quality scores, and pain pattern scores than both cancer groups, the SCD group was more satisfied with the pain level than the raceconcordant cancer group. The finding regarding satisfaction is not surprising because over their lifetime, the SCD group had likely experienced more intense pain during sickle cell crisis than they reported during the outpatient visit.
The finding that the SCD group was more likely to report pain not as bad as expected than the race discordant group suggests that the SCD group would expect more severe pain as their condition changed. For patients with SCD, the findings regarding their expectation of pain may relate to the more intense crisis pain the patients with SCD had experienced throughout their lives. At a routine outpatient clinic visit, patients may expect their pain to be less than their crisis pain, which is usually managed at an acute care center, emergency department, or inpatient unit (Benjamin, Swinson, & Nagel, 2000; Wilkie, Johnson, Mack, Labotka, & Molokie, 2010a) .
If institutional expertise in caring for minority patients was instrumental for better pain care as we speculated, one would expect that outpatients with cancer who are predominantly African Americans would also report less pain intensity, as did outpatients with SCD, because both groups were cared for in the same minority-serving institution. Our findings suggest the contrary. Instead, the outpatients with cancer who are predominantly African Americans reported higher worst pain intensity than the outpatients with cancer who are predominantly Caucasians and the outpatients with SCD. Two factors could be at play. First, cancer is known to be a disease of old age (White et al., 2014) . It is plausible that patients with cancer who are predominantly African Americans diagnosed with cancer at an older age may not have similar levels of relationships, as did outpatients with SCD usually diagnosed at birth, necessary to form bonds and mutual trust that foster improved pain care, as we saw in the case of outpatients with SCD . Second, it is possible that our findings support the current research evidence on the existence of historical and contemporary racial disparities in pain treatment of patients with cancer (Bernabei et al., 1998; Ezenwa et al., 2006) . Researchers could decipher our assertions in future studies of direct comparison between patients with SCD and those with cancer from the same minorityserving institution in the same study.
It is worth noting that all patient groups, race discordant, race concordant, and SCD, were able to provide pain scores using a valid pain measure, PAINReportIt, a computerized version of the McGill Pain Questionnaire. Patients' ability to reliably self-report their pain will help mitigate decades of racial disparities in pain assessment and its management where African Americans fare worse, especially when health care providers were in charge of reporting pain of minority patients. For example, evidence from a systematic review indicates that providers are more likely to underreport pain of minority patients and are also more likely not to document the pain of minority patients compared with Whites (Cintron & Morrison, 2006) . That the African Americans in this study easily used the computerized pain measure is contrary to popular belief that the digital divide would likely prevent them from using the technology. The Pew report indicates that the likelihood of African Americans' and Hispanics' owning and using smart phones to access their health information on the Internet is higher than that of their Caucasian counterparts (Fox & Duggan, 2012) . Further, the African Americans who own cell phones are more likely than Caucasians to use their cell phones for the purpose of tracking their health outcomes via text messages and downloaded applications (Fox & Duggan, 2012) . To extrapolate this finding to patients with SCD who are mostly African Americans, it is very probable that the use of modern technology will be extremely instrumental in assessing and subsequently managing sickle cell pain, as has been supported by our research (Ezenwa et al., 2016c; Jha et al., 2010) and that of others (McClellan et al., 2009; Shah, Jonassaint, & De Castro, 2014) . Perhaps, part of the effort in modeling an SCD pain treatment protocol after that of cancer would include leveraging computer technology to track patients' pain and encouraging patients to promptly manage pain at its onset and to visit a day hospital or acute care center before the pain becomes unbearable and difficult to manage at home .
Despite our novel and interesting findings, some limitations detracted from the findings. All three samples were convenient samples, and it is unclear how representative they are of the patients served in the three settings within the two geographically distant institutions. The analyses reported here do not take into consideration analgesics or other factors such as stage of disease and preexisting chronic pain in patients with cancer that could have influenced the reported pain. Finally, other types of disparities, such as age and gender disparities, may be operating within the three samples. We did not focus on age and gender disparities in pain management because they were outside the scope of the current study, but we will evaluate them in future research.
Our study findings have both research and practice implications. With respect to research, clearly, number of pain location sites, pain quality, and pattern are important sensory pain parameters that contribute to pain experience for patients with SCD. Pain researchers ought to evaluate these pain components in other pain patient populations including cancer patients to have a comprehensive understanding of pain experience other than pain intensity as is the status quo. Regarding practice implications for our findings, the fact that cancer patients who are predominantly African American reported worst pain intensity greater than that of their counterparts who are predominantly Caucasians indicates that racial disparities in pain management are still a major issue in the United States. Educational interventions for health care providers that focus on empathy and human dignity could incentivize them to assess correctly and optimally treat pain in minority patients without bias to ameliorate racial disparities in pain management.
CONCLUSIONS
We found that outpatients with SCD reported a greater number of pain location sites and higher pain quality and pattern scores than outpatients with cancer, but reported lower worst pain intensity in the previous 24 hours than race-concordant patients with cancer. Outpatients with SCD also reported that they were less dissatisfied with their pain level at the time of a clinic visit than race-concordant patients with cancer were. These findings may relate to the more intense and recurrent crisis pain that the patients with SCD had experienced throughout their lives. Although SCD crisis pain is known to be severe, our findings suggest that outpatients with SCD also report pain that is moderate to severe. In outpatients with SCD, three of the four pain parameters were greater than those reported by cancer outpatients, including a predominately African American sample of patients with cancer. These findings will be helpful for planning future research on appropriate pain treatment protocols for different pain populations.
